Entry Inhibitors

Entry inhibitors work by preventing HIV from entering healthy CD4 cells (T-cells) in the body. They work differently than many of the approved anti-HIV drugs—the protease inhibitors (PIs), the nucleoside reverse transcriptase inhibitors (NRTIs), and the non-nucleoside reverse transcriptase inhibitors (NNRTIs)—which are active against HIV after it has infected a CD4 cell.

Entry inhibitors work by attaching themselves to proteins on the surface of CD4 cells or proteins on the surface of HIV. In order for HIV to bind to CD4 cells, the proteins on HIV's outer coat must bind to the proteins on the surface of CD4 cells. Entry inhibitors prevent this from happening. Some entry inhibitors target the gp120 or gp41 proteins on HIV's surface. Some entry inhibitors target the CD4 protein or the CCR5 or CXCR4 receptors on a CD4 cell's surface. If entry inhibitors are successful in blocking these proteins, HIV is unable to bind to the surface of CD4 cells and gain entry into the cells.

HIV-positive people who have become resistant to PIs, NRTIs, and NNRTIs will likely benefit from the entry inhibitors because they are a different class of drugs. This is good news for HIV-positive people who have tried and failed many of the currently approved anti-HIV medications.

*generic or biosimilar available

E experimental

DRUG Fuzeon
GENERIC NAME enfuvirtide
COMPANY Genentech, a division of Roche
DRUG Rukobia
Rukobia fostemsavir ViiV Healthcare
GENERIC NAME fostemsavir
COMPANY ViiV Healthcare
DRUG Selzentry
GENERIC NAME maraviroc
COMPANY ViiV Healthcare
DRUG Trogarzo
COMPANY TaiMed Biologics and Theratechnologies
Leronlimab (PRO 140)
GENERIC NAME leronlimab

Last Reviewed: May 20, 2019


Hot topics